68Ga-PSMA−, 18F-FDG+ Lesion Validation
| Patients | Gleason score | PSA (ng/mL) | Lesions (n) | Lesions with 68Ga-PSMA−, 18F-FDG+ findings | Validated lesion | Validation method |
|---|---|---|---|---|---|---|
| 1 | 9 | 0.4 | 1 | Bone | Bone | Conventional imaging |
| 2 | 9 | 2.0 | 2 | Pelvic lymph nodes | Pelvic lymph nodes | Conventional imaging |
| 3 | 8 | 8.0 | 1 | Bone | Bone | Conventional imaging |
| 4 | 9 | 4.6 | 3 | Pelvic lymph nodes | Pelvic lymph nodes | Conventional imaging |
| 5 | 9 | 31.0 | 1 | Bone | Bone | Conventional imaging |
| 6 | 8 | 0.9 | 1 | Bone | Bone | Conventional imaging |
| 7 | 9 | 86.0 | 2 | Pelvic lymph nodes | Pelvic lymph nodes | Conventional imaging |
| 8 | 9 | 8.9 | 7 | Pelvic lymph nodes, bone | Pelvic lymph nodes | 18F-FDG PET/CT |
| 9 | 9 | 18.4 | 1 | Extrapelvic lymph nodes | Extrapelvic lymph nodes | 18F-FDG PET/CT |
| 10 | 8 | 2.1 | 1 | Pelvic lymph nodes | Pelvic lymph nodes | PSA response after SBRT |
| 11 | 9 | 84.7 | 2 | Pelvic lymph nodes | Pelvic lymph nodes | PSA response after SBRT |
| 12 | 8 | 8.0 | 10 | Local recurrence, pelvic lymph nodes, inguinal lymph nodes, bone | Inguinal lymph nodes | Pathologic confirmation |
| 13 | 9 | 15.9 | 2 | Pelvic lymph nodes and bone | Bone | Pathologic confirmation |
Conventional imaging = CT, MRI, or bone scintigraphy; SBRT = stereotactic body radiotherapy.